Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
(d) On January 7, 2020, the Board of Directors (the "Board") of Diffusion
Pharmaceuticals Inc. (the "Company") appointed Robert J. Cobuzzi, Ph.D. as
director of the Company. Upon Dr. Cobuzzi's appointment as a director of the
Company, the size of the Board was expanded from five to six members. Dr.
Cobuzzi does not currently serve on any committees of the Company.
Dr. Cobuzzi, age 55, currently serves as Advisor of the Mitochondrial Disease
Research Program at the Children's Hospital of Philadelphia, an internationally
recognized hospital and research center devoted to children. From 2005 to 2018,
Dr. Cobuzzi served in various roles at Endo International PLC, a specialty
branded and generic pharmaceuticals manufacturer with approximately $3 billion
in revenue and 5,000 employees as of December 31, 2018, most recently serving as
President of Endo Ventures Ltd. Dr. Cobuzzi currently serves as Chairman of the
Business Development Board of Sunstone Life Science Ventures, an early-stage,
European focused investor in human therapeutics. Dr. Cobuzzi received his
Bachelor of Arts in Biochemistry and Art History from Colby College and his
Ph.D. in Molecular and Cellular Biochemistry from Loyola University Chicago. He
served as a Post-doctoral Fellow in Experimental Therapeutics at Roswell Park
Cancer Institute.
In connection with his appointment to the Board, on January 7, 2020 Dr. Cobuzzi
was granted stock options to purchase 118,600 shares of the Company's common
stock with an exercise price of $0.42 per share (the "Option Grant"). Dr.
Cobuzzi was also granted, on January 7, 2020, restricted stock units
representing 98,100 shares of the Company's common stock (the "RSU Grant"). The
Option Grant will vest in 18 equal monthly installments on the last calendar day
of the next 18 months and the RSU Grant will vest in six (6) equal quarterly
installments on the last calendar day of each quarter over the 18 month period
beginning on July 1, 2021. In addition to the Option Grant and the RSU Grant,
Dr. Cobuzzi will also receive an annual retainer and other compensation payable
to the Company's non-employee directors as described in the Company's filings
with the Securities and Exchange Commission.
There are no arrangements or understandings between Dr. Cobuzzi and any other
persons pursuant to which Dr. Cobuzzi was selected as a director of the Company.
There are also no family relationships between Dr. Cobuzzi and any director or
executive officer of the Company.
Additional information regarding Dr. Cobuzzi's appointment as a director is
contained in the press release attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1 Press Release, dated as of January 10, 2020, announcing the appointment
of a new director.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses